4:59 PM · 11 March 2024

Moderna rallies 9% on vaccine trials

Moderna (MRNA.US) is the best performing company in S&P 500 index today, gaining around 9% at press time. Gains were triggered by the announcement on the government trial website that the company is starting a mid-stage study of the experimental cancer vaccine in patients with cutaneous squamous carcinoma. Trial to test the vaccine will be in collaboration with Merck & Co (MRK.US). Results of a study on another Moderna-Merck vaccine showed in December 2023 reduce risk of severe skin cancer recurrence for three years.

Taking a look at Moderna (MRNA.US) chart at D1 interval, we can see that the stock surged today and climbed to the highest level since January 8, 2024. Share price is approaching a resistance zone in the $116 area, marked with previous local highs. A break above it would open the way towards the next major resistance zone to watch, which can be found in the $128.50 area.

Source: xStation5

4 June 2026, 3:26 PM

US Open: weaker labor market and AI weigh on Wall Street ❗

4 June 2026, 1:39 PM

EU Wrap: session remains stable amid sector rotation 🔎

4 June 2026, 9:54 AM

Broadcom beats forecasts, yet shares fall nearly 13% ⚔️

3 June 2026, 6:55 PM

Daily Summary: Markets take a breather (03.06.2026)

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits